Patents by Inventor Colette Cote

Colette Cote has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Reagents, methods, and systems for detecting methicillin-resistant
    Patent number: 8735554
    Abstract: The present invention provides PBP2a peptide antigens for generating antibodies against MRSA, and provides high-affinity binding agents that detect MRSA by selective immunoreactivity with PBP2a. The antibodies are useful in methods and systems for detecting MRSA, including biosensor systems, or as components of diagnostic or detection kits. The antibodies, in some embodiments, have therapeutic value against MRSA infection.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: May 27, 2014
    Assignee: Innovative Biosensors, Inc.
    Inventors: Colette Cote, Qiao-xi Zheng, Venkatakrishna Shyamala, Tom Hazel
  • Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing
    Patent number: 8053232
    Abstract: The present invention provides methods and compositions for generating novel nucleic acid molecules through targeted spliceosomal mediated RNA trans-splicing. The compositions of the invention include pre-trans-splicing molecules (PTMs) designed to interact with a SERPINA1 target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA). In particular, the PTMs of the present invention include those genetically engineered to interact with SERPINA1 target pre-mRNA so as to result in correction of SERPINA1 genetic defects responsible for AAT deficiency. The PTMs of the invention may also comprise sequences that are processed out of the PTM to yield duplex siRNA molecules directed specifically to mutant SERPIN A1 mRNAs. Such duplexed siRNAs are designed to reduce the accumulation of toxic AAT protein in liver cells.
    Type: Grant
    Filed: January 21, 2005
    Date of Patent: November 8, 2011
    Assignee: VIRxSYS Corporation
    Inventors: Madaiah Puttaraju, Edward Otto, Mariano A. Garcia-Blanco, Gerard J. McGarrity, Gary F. Temple, Lloyd G. Mitchell, Colette Cote, S. Gary Mansfield
  • REAGENTS, METHODS, AND SYSTEMS FOR DETECTING METHICILLIN-RESISTANT STAPHYLOCOCCUS
    Publication number: 20110250202
    Abstract: The present invention provides PBP2a peptide antigens for generating antibodies against MRSA, and provides high-affinity binding agents that detect MRSA by selective immunoreactivity with PBP2a. The antibodies are useful in methods and systems for detecting MRSA, including biosensor systems, or as components of diagnostic or detection kits. The antibodies, in some embodiments, have therapeutic value against MRSA infection.
    Type: Application
    Filed: May 7, 2009
    Publication date: October 13, 2011
    Applicant: Innovative Biosensors, Inc.
    Inventors: Colette Cote, Qiao-Xi Zheng, Venkatakrishna Shyamala, Tom Hazel
  • Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing
    Publication number: 20060234247
    Abstract: The present invention provides methods and compositions for generating novel nucleic acid molecules through targeted spliceosomal mediated RNA trans-splicing. The compositions of the invention include pre-trans-splicing molecules (PTMs) designed to interact with a SERPINA1 target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA). In particular, the PTMs of the present invention include those genetically engineered to interact with SERPINA1 target pre-mRNA so as to result in correction of SERPINA1 genetic defects responsible for AAT deficiency. The PTMs of the invention may also comprise sequences that are processed out of the PTM to yield duplex siRNA molecules directed specifically to mutant SERPIN A1 mRNAs. Such duplexed siRNAs are designed to reduce the accumulation of toxic AAT protein in liver cells.
    Type: Application
    Filed: January 21, 2005
    Publication date: October 19, 2006
    Inventors: Madaiah Puttaraju, Edward Otto, Mariano Garcia-Blanco, Gerard McGarrity, Gary Temple, Lloyd Mitchell, Colette Cote, S. Mansfield